Results 261 to 270 of about 2,823,581 (316)

A New Series of Cholinesterase Inhibitors*

Journal of the American Pharmaceutical Association (Scientific ed.), 1954
In a series of bis onium biphepyl derivatives, alteration of substitutions on the quaternary nitrogen produced a wide variation in toxicity and ability to inhibit cholinesterase, as well as other pharmacological responses. Three members of this series were found to be equal to neostigmine bromide as inhibitors of bovine erythrocyte cholinesterase ...
John P. Long, F.W. Schueler
openaire   +3 more sources

Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta‐Analysis and Systematic Review

Journal of The American Geriatrics Society, 2018
To evaluate the cardiovascular (CV) effects of acetylcholinesterase inhibitors (AChEIs) in individuals with ...
A. Işık, P. Soysal, B. Stubbs, M. Solmi, C. Basso, S. Maggi, P. Schofield, N. Veronese, C. Mueller   +8 more
semanticscholar   +1 more source

Pharmacokinetic studies of cholinesterase inhibitors

Acta Neurologica Scandinavica, 2009
The pharmacokinetic of some centrally acting cholinesterase inhibitors that have been used to improve memory in patients with dementia of Alzheimer's type, was compared. The original compound in this class, physostigmine has an elimination half-life of 20-30 min.
M. Johansson, Agneta Nordberg
openaire   +3 more sources

Ten years of cholinesterase inhibitors

International Journal of Geriatric Psychiatry, 2009
AbstractIn this editorial we have summarised ten years of evidence relating to the use of cholinesterase inhibitors in Alzheimer's and other dementias. We have presented this evidence in the context of the evolution of public and professional awareness of dementia and its management and prescribing patterns over this time frame. We also briefly outline
Joanne Rodda, Zuzana Walker
openaire   +3 more sources

Cholinesterase Inhibitors for Alzheimer??s Disease

Drugs, 2001
Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available.
John C. Morris, Jaime Grutzendler
openaire   +3 more sources

ABCpred: a webserver for the discovery of acetyl- and butyryl-cholinesterase inhibitors

Molecular diversity, 2021
A. Malik, S. Ojha, N. Schaduangrat, C. Nantasenamat   +3 more
semanticscholar   +1 more source

Variability in the Prescription of Cholinesterase Inhibitors and Memantine

Dementia and Geriatric Cognitive Disorders, 2009
<i>Background/Aim:</i> To estimate the prevalence of Alzheimer’s disease (AD) treatment in Aragon (Spain), analyzing differences according to age, gender and health area. <i>Methods:</i> Retrospective study on AD treatment prevalence of cholinesterase inhibitors and memantine during 2005, using pharmaco-epidemiological data from
Villar-Fernández, I, Bjerrum, L, Feja, C, Rabanaque, M J   +3 more
openaire   +5 more sources

The next generation of cholinesterase inhibitors

Acta Neurologica Scandinavica, 2009
Clinical trials with tacrine (THA) have resulted in elevations of liver enzymes in Alzheimer patients that showed improvement. In an effort to minimize these side effects several THA analogues were synthesized. These analogues were compared to THA in biochemical as well as behavioural studies.
openaire   +3 more sources

Pulmonary mechanical responses to cholinesterase inhibitor

Fundamental and Applied Toxicology, 1989
Lung static and dynamic compliances, and lung and upper airway resistances were measured in pentobarbital-anesthetized dogs before and after intravenous administration of 2 LD50 of the organophosphate cholinesterase inhibitor pinacolyl methylphosphonofluoridate (GD), followed by 1 mg of atropine 8 min later.
H. J. Bryant, Richard R. Kyle, Peter H. Abbrecht   +2 more
openaire   +3 more sources

Cholinesterase Inhibitors for Alzheimer's Disease

Hospital Practice, 1998
New cholinesterase inhibitors capable of slowing the progression of Alzheimer's disease are being introduced at a rapid pace. In prescribing these drugs and setting realistic expectations for outcome, it is necessary to understand that they affect cholinergic activity in other tissues as well as the brain.
openaire   +3 more sources